Leiden, The Netherlands, 9 January 2008 - Dutch biotechnology company Crucell N.V. today released preliminary results in which the company announced that it generated a positive cash flow of over EUR 5 million in 2007. Net operational cash flow increased to over EUR 18 million compared to previous guidance of break-even. Operational cash flow in 2006 was EUR 54 million negative. The company revised its revenue and operating income guidance for the year 2007 to EUR 213 million. The revision was made in the light of revenue recognition of an agreement it entered into with Sanofi Pasteur and persistent weakness in the U.S. dollar in the final quarter of 2007. Revenues and operating income in 2007 increased by more than 50% over reported revenues in 2006.
